Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of “Buy” by Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA) has been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $64.67.

VERA has been the subject of several recent research reports. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price for the company. Wolfe Research started coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on Vera Therapeutics in a report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target on the stock.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the transaction, the chief executive officer now owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 21.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently bought and sold shares of the stock. First Turn Management LLC lifted its position in Vera Therapeutics by 53.3% in the third quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock worth $14,431,000 after purchasing an additional 113,550 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Vera Therapeutics by 116.7% in the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock valued at $857,000 after buying an additional 10,916 shares during the period. Lord Abbett & CO. LLC boosted its stake in Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after buying an additional 124,197 shares in the last quarter. Barclays PLC boosted its stake in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock valued at $3,774,000 after buying an additional 41,394 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Vera Therapeutics by 3.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company’s stock worth $15,992,000 after acquiring an additional 10,717 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $27.34 on Wednesday. The firm has a market cap of $1.74 billion, a PE ratio of -10.48 and a beta of 1.17. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61. The firm’s 50-day simple moving average is $32.43 and its 200-day simple moving average is $39.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. Equities analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.